Asset Acquisition, Contingent Consideration, Current

No definition available.

Name:	dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business Combination, Percentage Of Purchase Price Exchanged

+ References

No definition available.

+ Details

Name:	dare_BusinessCombinationPercentageOfPurchasePriceExchanged
Namespace Prefix:	dare_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Expiration Period

+ References

No definition available.

+ Details

Name:	dare_LicenseAgreementExpirationPeriod
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Number Of Experts

+ References

No definition available.

+ Details

Name:	dare_LicenseAgreementNumberOfExperts
Namespace Prefix:	dare_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Maximum Potential Milestone Payments

+ References

No definition available.

+ Details

Name:	dare_MaximumPotentialMilestonePayments
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments, contingent amount.

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments, Contingent Amount, First Commercial Sale Amount

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmountFirstCommercialSaleAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone Payments, Contingent Amount, Sales Based Milestones Amount

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmountSalesBasedMilestonesAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsReimburseAmountPDUFAFeesAndOtherManufacturingExpenses
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payment of Additional Consideration in Business Combination

+ References

No definition available.

+ Details

Name:	dare_PaymentOfAdditionalConsiderationInBusinessCombination
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments to Stockholders' Representative in Business Combination

+ References

No definition available.

+ Details

Name:	dare_PaymentsToStockholdersRepresentativeInBusinessCombination
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Annual License Maintenance Fee Payments, Thereafter

+ References

No definition available.

+ Details

Name:	dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research and development milestone payment.

+ References

No definition available.

+ Details

Name:	dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue, Number Of Significant Performance Obligations

+ References

No definition available.

+ Details

Name:	dare_RevenueNumberOfSignificantPerformanceObligations
Namespace Prefix:	dare_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty Rate, Percentage

+ References

No definition available.

+ Details

Name:	dare_RoyaltyRatePercentage
Namespace Prefix:	dare_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront License Fee, Advanced Written Notice, Period

+ References

No definition available.

+ Details

Name:	dare_UpfrontLicenseFeeAdvancedWrittenNoticePeriod
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront License Fee, Amount Paid

+ References

No definition available.

+ Details

Name:	dare_UpfrontLicenseFeeAmountPaid
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=dare_LicenseAndCollaborationRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_HennepinLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_LicensedProductOrProcessForVaginalOrUrologicalUseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_MergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_PearTreePharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_DouglasLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_OrganonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_CatalentAndMilanaPharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_FormerStockholdersOfMBIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_BayerHealthcareLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dare_RoyaltyRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dare_TheramexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_TheramexCoDevelopmentAndLicensingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Strategic Agreements - Additional Information (Details)	1 Months Ended												3 Months Ended				12 Months Ended
Strategic Agreements - Additional Information (Details)	Feb. 28, 2025	Jul. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)	Sep. 30, 2021 USD ($) shares	Jun. 30, 2021 USD ($)	Jan. 31, 2020 USD ($) expert obligation	Nov. 30, 2019 USD ($)	May 31, 2018 USD ($)	Apr. 30, 2018 USD ($)	Feb. 28, 2018 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023	Dec. 31, 2024 USD ($)	Dec. 31, 2021 USD ($)	Aug. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue													$ 25,427	$ 9,302
License And Collaboration Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue													12,800,000
Upon Achievement of Specified Development and Regulatory Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													50,000,000.0
Microchips Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of additional consideration						$ 1,250,000							0
Microchips Biotech, Inc. \| Upon Achievement of Specified Development and Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments								$ 46,500,000
Current portion of contingent consideration								$ 55,000,000.0
ADVA Tec Agreement \| Upon Achievement of Specified Development and Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments												$ 14,600,000
ADVA Tec Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty rate												1.00%
ADVA Tec Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty rate												10.00%
Bayer Healthcare License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of experts \| expert							2
Number of significant performance obligations \| obligation							1
Milestone payments, contingent amount							$ 310,000,000.0
Bayer Healthcare License Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Expiration period																15 years
Hennepin License Agreement \| Clinical and Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments			$ 6,250,000
Hennepin License Agreement \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments			$ 45,000,000.0
Licensing Agreements \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													1,000,000.0
Licensing Agreements \| Upon Achieving Certain Commercial Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													850,000
Licensing Agreements \| Licensed Product or Process for Vaginal or Urological Use \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													250,000
Licensing Agreements \| Maximum \| Upon Achieving Certain Development Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount															$ 500,000			$ 300,000
Licensing Agreements \| Upon Achievement of Specified Development and Regulatory Milestones \| Upon Achieving Certain Commercial Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount												$ 1,200,000	1,200,000
Licensing Agreements \| ADVA Tec Agreement \| Upon Reaching Certain Worldwide Net Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments												$ 20,000,000.0
Assignment Agreement \| Upon Achieving Certain Clinical and Regulatory Development Milestones \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													1,100,000
Merger Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments									$ 15,500,000
Milestone payments									3,200,000
Pear Tree Pharmaceuticals, Inc. \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments									$ 47,000,000.0
Juniper Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid										$ 250,000
Potential annual license maintenance fee payments, thereafter										100,000
Juniper Pharmaceuticals, Inc \| Clinical and Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments										13,500,000
Juniper Pharmaceuticals, Inc \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments										$ 30,300,000
License and Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount											$ 18,000,000.0
License and Collaboration Agreement \| Upon Achieving Certain Commercial Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount											$ 100,000,000.0						$ 1,000,000
Douglas License Agreement \| Upon Achieving Certain Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales based milestones amount																			$ 5,250,000
Douglas License Agreement \| Upon Achieving Certain Commercial Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales based milestones amount																			$ 64,000,000
Organon
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales based milestones amount													$ 180,000,000.0
Upfront license fee paid				$ 10,000,000.0
Milestone payments, reimburse amount, PDUFA fees and other manufacturing expenses		$ 1,000,000
First commercial sale amount															$ 1,800,000
Advanced written notice period													120 days
Catalent and MilanaPharm \| Licensing Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													$ 1,000,000
Former Stockholders of MBI \| Microchips Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock, net of issuance costs (in shares) \| shares					58,334
Cash paid to stockholders' representative					$ 75,000
Bayer \| Collaborative Arrangement \| Royalty Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue							$ 20,000,000.0
Upfront license fee paid													$ 1,000,000.0				$ 1,000,000.0
Advanced written notice period							90 days
Theramex \| Theramex Co-Development And Licensing Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of purchase price exchanged	50.00%